Science and Health News

New research from the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London has established a blood-based test that could be used to predict the risk of Alzheimer’s disease up to 3.5 years before clinical diagnosis.

The U.S. Food and Drug Administration approved Leqembi (lecanemab-irmb) via the Accelerated Approval pathway for the treatment of Alzheimer’s disease.

A group of neuroscientists led by a University of Pittsburgh School of Medicine researcher developed a test to detect a novel marker of Alzheimer’s disease neurodegeneration in a blood sample.

MIT researchers report early-stage clinical study results of tests with noninvasive 40-hertz light and sound treatment.

A mutation in the small protein SHMOOSE is associated with Alzheimer’s risk and highlights a possible target for treatment.

Infections treated with specialty hospital care in early- and mid-life are associated with an increased subsequent risk of Alzheimer’s and Parkinson’s diseases, but not amyotrophic lateral sclerosis (ALS), according to a study by researchers from Karolinska Institutet, published in PLOS Medicine.

With a $45 million grant from the National Institutes of Health and National Institute on Aging, the Alzheimer’s Disease Cooperative Study (ADCS) at University of California San Diego, in collaboration with Burke Neurological Institute (BNI) and Columbia University Irving Medical Center, will launch a nationwide clinical trial to further investigate the therapeutic potential of benfotiamine, a synthetic version of thiamine (B1), as a metabolic treatment approach to Alzheimer’s disease.

A novel, disease-modifying therapy for Alzheimer’s disease may involve the whole exchange of blood, which effectively decreased the formation of amyloid plaque in the brains of mice, according to a new study from UTHealth Houston.